86604-75-3Relevant articles and documents
Syntheses and Crystal Structures of 2-Chloromethyl-3,5-dimethyl-4-methoxy/ethoxy-pyridines and Their Methylsulphinyl Derivatives
Ma, Sen,Chen, Min,Fan, Fang-Fang,Jia, Ai-Quan,Zhang, Qian-Feng
, p. 64 - 71 (2018)
Abstract: Treatment of 2-(chloromethyl)-pyridine derivatives 3,5-dimethyl-4-(alkoxy)-2-(chloromethyl)-pyridine hydrochloride (alkoxy = methoxy, 1; ethoxy, 2) with 1-(4-chloro-phenyl)imidazole-2-thione in the presence of sodium methoxide afforded the corresponding methylsulphinyl derivatives 3,5-dimethyl-[4-(alkoxy)-2-pyridinyl]-methylthio-1-(4-chloro-phenyl)-imidazole (alkoxy = methoxy, 3; ethoxy, 4). Similarly, reaction of 1 or 2 with 4,6-dimethyl-pyrimidine-2-thiol gave the methylsulphinyl derivatives 3,5-dimethyl-[4-(alkoxy)-2-pyridinyl]-methylthio-4,6-dimethyl-pyrimidine (alkoxy = methoxy, 5; ethoxy, 6). While reaction of 5 with CuCl2·2H2O in methanol produced a square-planar copper(II) complex, trans-bis{3,5-dimethyl-[4-(methoxy)-2-pyridinyl]-methylthio-4,6-dimethyl-pyrimidine}-dichloro-copper(II) (7). The crystal structures of 1, 2, 4?HCl?2H2O, and 7, along with their spectroscopic properties are reported. The weak hydrogen-bonding interactions exist in compounds 1, 2, and 4?HCl?2H2O. Compound 1 crystallizes in the monoclinic space group P21/c with a = 6.074(11), b = 19.88(4), c = 9.230(16)??, β = 99.67(4)°, and Z = 4. Compound 2 crystallizes in the monoclinic space group P21/n with a = 10.0103(15), b = 7.9905(12), c = 15.120(2) ?, β = 93.924(2), and Z = 4. The unit cells of both 4?HCl?2H2O and 7 have triclinic P-1 symmetry with the cell parameters a = 7.492(8), b = 10.170(12), c = 15.723(18) ?, α = 77.159(15)°, β = 91.113(13)°, γ = 81.194(16)°, and V = 1152(2)??3 for 4?HCl?2H2O and a = 10.526(2), b = 12.936(2), c = 14.455(3)??, α = 107.929(2)°, β = 93.686(2)°, γ = 104.095(3)°, and V = 1734.3(6) ?3 for 7. Graphical Abstract: Interaction of 3,5-dimethyl-[4-(methoxy)-2-pyridinyl]-methylthio-4,6-dimethyl-pyrimidine and CuCl2·2H2O in methanol resulted in the formation of a square-planar copper(II) complex, trans-bis{3,5-dimethyl-[4-(methoxy)-2-pyridinyl]-methylthio-4,6-dimethyl-pyrimidine}-dichloro-copper(II), which was structurally characterized.
Preparation method of omeprazole intermediate
-
Paragraph 0063-0064; 0066; 0067-0068; 0070; 0071-0072; 0074, (2021/01/15)
The invention relates to a preparation method of an omeprazole intermediate. According to the method, Nmethoxy-4-methoxy3, 5-dimethyl pyridinium is used as a raw material, metal ions are added as an additive, under the action of persulfate, 2-hydroxymethyl- 3, 5-dimethyl -4methoxypyridine is efficiently prepared, and then the 2-hydroxymethyl -3, 5-dimethyl- 4-methoxypyridine is further converted into 2-chloromethyl -3, 5-dimethyl- 4methoxypyridine hydrochloride. According to the method, the conversion rate, the yield and the quality of the 2-hydroxymethyl- 3, 5-dimethyl -4-methoxy pyridine areremarkably improved, so that the purity of the 2-chloromethyl- 3, 5-dimethyl- 4-methoxy pyridine hydrochloride obtained by further reaction is improved, the impurity content is reduced, the product yield and the production efficiency can be effectively improved, the production capacity is improved, and the production cost is reduced.
Esomeprazole sodium and lyophilized preparation comprising same
-
Paragraph 0038; 0039; 0040, (2019/03/28)
The invention provides esomeprazole sodium and a lyophilized preparation comprising the same. A preparation method of esomeprazole sodium includes following steps: 1), synthesizing an intermediate; 2), synthesizing esomeprazole sodium; 3), roughly preparing esomeprazole sodium; 4), finely preparing esomeprazole sodium. Esomeprazole sodium prepared by the method is higher in preparation accuracy and safer to use; the preparation process is easier to control, and step decomposition brings convenience to quality control of middle steps, so that ensuring of preparation accuracy of esomeprazole sodium is facilitated, and drug prepared from esomeprazole sodium is safer.